162 related articles for article (PubMed ID: 29028101)
1. TopBP1 promotes malignant progression and correlates with poor prognosis in osteosarcoma.
Wu DP; Yan XB; Liu LG; Tian C; Han K; Zhang H; Min DL
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4022-4031. PubMed ID: 29028101
[TBL] [Abstract][Full Text] [Related]
2. TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53.
Lv Y; Huo Y; Yu X; Liu R; Zhang S; Zheng X; Zhang X
Drug Des Devel Ther; 2016; 10():3053-3064. PubMed ID: 27729767
[TBL] [Abstract][Full Text] [Related]
3. CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma.
Ma C; Nie XG; Wang YL; Liu XH; Liang X; Zhou QL; Wu DP
Mol Med Rep; 2019 May; 19(5):4205-4212. PubMed ID: 30942427
[TBL] [Abstract][Full Text] [Related]
4. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
[TBL] [Abstract][Full Text] [Related]
5. Podocalyxin promotes cisplatin chemoresistance in osteosarcoma cells through phosphatidylinositide 3-kinase signaling.
Huang Z; Huang Y; He H; Ni J
Mol Med Rep; 2015 Sep; 12(3):3916-3922. PubMed ID: 26017117
[TBL] [Abstract][Full Text] [Related]
6. miR-491 Inhibits Osteosarcoma Lung Metastasis and Chemoresistance by Targeting αB-crystallin.
Wang SN; Luo S; Liu C; Piao Z; Gou W; Wang Y; Guan W; Li Q; Zou H; Yang ZZ; Wang D; Wang Y; Xu M; Jin H; Xu CX
Mol Ther; 2017 Sep; 25(9):2140-2149. PubMed ID: 28648665
[TBL] [Abstract][Full Text] [Related]
7. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
[TBL] [Abstract][Full Text] [Related]
8. The c.*229C > T gene polymorphism in 3'UTR region of the topoisomerase IIβ binding protein 1 gene and LOH in BRCA1/2 regions and their effect on the risk and progression of human laryngeal carcinoma.
Starska K; Forma E; Nowacka-Zawisza M; Lewy-Trenda I; Ciesielski P; Pietruszewska W; Skóra M; Bryś M
Tumour Biol; 2016 Apr; 37(4):4541-57. PubMed ID: 26503213
[TBL] [Abstract][Full Text] [Related]
9. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
Pu Y; Zhao F; Li Y; Cui M; Wang H; Meng X; Cai S
BMC Cancer; 2017 Jan; 17(1):45. PubMed ID: 28073349
[TBL] [Abstract][Full Text] [Related]
10. Fascin-1 enhances experimental osteosarcoma tumor formation and metastasis and is related to poor patient outcome.
Arlt MJ; Kuzmanov A; Snedeker JG; Fuchs B; Silvan U; Sabile AA
BMC Cancer; 2019 Jan; 19(1):83. PubMed ID: 30654764
[TBL] [Abstract][Full Text] [Related]
11. RNA interference-mediated knockdown of Livin suppresses cell proliferation and invasion and enhances the chemosensitivity to cisplatin in human osteosarcoma cells.
Li X; Fan S; Li L; Wang L; Fan G; Zhao Q; Li Y
Int J Oncol; 2013 Jul; 43(1):159-68. PubMed ID: 23632777
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.
Wang Z; Liu Z; Wu S
Oncotarget; 2017 May; 8(19):31465-31477. PubMed ID: 28415557
[TBL] [Abstract][Full Text] [Related]
13. Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1.
Kun-Peng Z; Xiao-Long M; Chun-Lin Z
Int J Biol Sci; 2018; 14(3):321-330. PubMed ID: 29559849
[TBL] [Abstract][Full Text] [Related]
14. Suppression of CLEC3A inhibits osteosarcoma cell proliferation and promotes their chemosensitivity through the AKT1/mTOR/HIF1α signaling pathway.
Ren C; Pan R; Hou L; Wu H; Sun J; Zhang W; Tian X; Chen H
Mol Med Rep; 2020 Apr; 21(4):1739-1748. PubMed ID: 32319617
[TBL] [Abstract][Full Text] [Related]
15. CEP55 promotes the proliferation and invasion of tumour cells via the AKT signalling pathway in osteosarcoma.
Xu L; Xia C; Sheng F; Sun Q; Xiong J; Wang S
Carcinogenesis; 2018 Apr; 39(4):623-631. PubMed ID: 29579156
[TBL] [Abstract][Full Text] [Related]
16. Silencing XIAP suppresses osteosarcoma cell growth, and enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin.
Qu Y; Xia P; Zhang S; Pan S; Zhao J
Oncol Rep; 2015 Mar; 33(3):1177-84. PubMed ID: 25572427
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma.
Yang J; Cheng D; Zhou S; Zhu B; Hu T; Yang Q
Int J Mol Sci; 2015 Dec; 16(12):28635-46. PubMed ID: 26633383
[TBL] [Abstract][Full Text] [Related]
18. XB130 expression in human osteosarcoma: a clinical and experimental study.
Wang X; Wang R; Liu Z; Hao F; Huang H; Guo W
Int J Clin Exp Pathol; 2015; 8(3):2565-73. PubMed ID: 26045762
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis.
Zhu KP; Zhang CL; Shen GQ; Zhu ZS
Int J Clin Exp Pathol; 2015; 8(8):8754-73. PubMed ID: 26464619
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents.
Sun J; Fu ZM; Fang CQ; Li JH
Chin Med J (Engl); 2007 Mar; 120(5):400-4. PubMed ID: 17376311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
